Table 2.
Comparison of data from Latin American and Puerto Rico studies of GBS associated with Zika virus infection.
| Country/ number of patients included/ (reference) | Number of samples tested by RT-PCR/ number positive (%) | Median time from viral symptoms to testing/ (IQR or range) | Cranial neuropathy | ICU admission/tracheostomy/ gastrostomy |
|---|---|---|---|---|
| Colombia/68/(10) | Serum 31/1 (3.2) CSF 30/3 (10) Urine 24/16 (66.6) |
16.5/(IQR: 11.5–19.7) | Bifacial palsy 34; bulbar cranial nerves 15; cranial nerves III, IV, and VI 7 | 40/NA/NA |
| Brazil/40*/(11) | Serum 40/3 (7.5) CSF 40/2 (5) |
6/(4–7) | Facial palsy 11; bifacial palsy 5; dysphagia 3 | 9/NA/NA |
| Puerto Rico/71/(12) | Serum 99/23 (23.2) CSF 31/1 (3.2) Urine 43/5 (11.6) Saliva 18/0 (0) |
9/(1–92) | Facial weakness 44; dysphagia 38; dysarthria 27 | 47/6/5 |
| Mexico/5/present report | Serum 5/3 CSF 5/2 Urine 5/3 Saliva 5/2 |
9/(IQR: 7.0–12.5) | Bifacial palsy 3; cranial nerves III, IV, and VI 3; cranial nerves IX and X in one | 2/2/2 |
*
27 had GBS, five had encephalitis, two had transverse myelitis, and one had chronic inflammatory demyelinating polyneuropathy. ICU, intensive care unit; NA, not available.